09:54 EST Kyverna Therapeutics (KYTX) Inc trading halted, volatility trading pause
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Reports Positive Phase 2 Trial Results
- Kyverna Therapeutics Reports Positive Phase 2 Trial Results
- Kyverna Therapeutics announces topline data from registrational KYSA-8 trial
- Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley
- Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases